LA JOLLA PHARMACEUTICAL CO (LJPC)

US5034596040 - Common Stock

6.22  0 (0%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2019 2020 2021 2022 2023 2024 2025 2026
Revenue
YoY % growth
23.05M
129.13%		33.42M
44.99%		75.72M
126.57%		53.839M
EBITDA
YoY % growth
-105.25M
44.50%		-33M
68.65%		23.494M
171.19%		N/AN/AN/AN/AN/A
EBIT
YoY % growth
-109.8M
43.42%		-35.84M
67.36%		21.831M
160.91%		2.276M
Operating Margin
-476.36%-107.24%28.83%4.23%
EPS
YoY % growth
-4.30
45.57%		-1.45
66.28%		0.57
139.31%		0.04

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q3 / 22 Q4 / 22
EPS
Q2Q % growth		0.04
Revenue
Q2Q % growth		14.545M
EBITDA
Q2Q % growth		N/AN/A
EBIT
Q2Q % growth		1.443M

Recent Earnings VS Estimates Surprises ()
PeriodReportedEstimateDifferenceSurprise
Q2 2022
Q2Q % growth		 0.08
-27.27%		0.000.08∞%
Q1 2022
Q2Q % growth		 -0.15
-135.71%		0.01-0.16-1,570.59%
Q4 2021
Q2Q % growth		 0.12
192.31%		0.040.08194.12%
Q3 2021
Q2Q % growth		 -0.08
81.40%		-0.07-0.01-12.04%
Recent Revenue VS Estimates Surprises

Reported revenue can not be compared with estimates as they are in different currencies. Reported data is in USD, while estimates are .

PeriodReportedEstimateDifferenceSurprise
Q2 2022
Q2Q % growth		 10.543M
-34.35%		13.107M-2.564M-19.56%
Q1 2022
Q2Q % growth		 10.425M
-69.46%		13.362M-2.937M-21.98%
Q4 2021
Q2Q % growth		 12.21M
11.51%		14.312M-2.102M-14.68%
Q3 2021
Q2Q % growth		 13.314M
46.79%		12.342M972K7.88%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPSN/A N/A N/A N/A
RevenueN/A N/A N/A N/A